To dampen periodic off-levelling motions within an inertial platform while undergoing horizontal accelerations of the same period and to achieve a levelling accuracy of a few tens of arcseconds with that system,an int...To dampen periodic off-levelling motions within an inertial platform while undergoing horizontal accelerations of the same period and to achieve a levelling accuracy of a few tens of arcseconds with that system,an internally damped inertial platform for a marine scalar gravity system was the developed.Methods for attenuating horizontal acceleration and reducing off-levelling error by a satisfactory gyro-levelling loop,which are fundamental to the internally damped inertial platform,were designed and implemented.In addition,phase delays are introduced by the levelling loop.The resulting off-levelling gravity errors were analyzed and modeled.A series of tests on a motion simulator were performed in laboratory for a variety of simulated sea conditions.We found that the motion of the platform is a function of the amplitude and period of the simulated ship motions and ranges between 10 and 40 arcseconds.In addition,the phase lag between platform motion and ship motion is not constant but ranges 180°-270°,depending on the period and amplitude of the motion.Then,the platform,on which a gravimeter was mounted,was installed on the R/V Shiyan 2 to conduct a gravity survey in the South China Sea.Despite rough sea conditions,it was shown that in short periods of 2-30 s,the off-levelling angle was less than 30 arcseconds,and the phase lagged the horizontal acceleration by 230°-260°.From a repeated survey line and intersecting survey points,the estimated errors of gravity measurements were between 1.3 and 1.7 mGal.The marine measurements results were compared with those of satellite altimetry data and show a mean value of 0.5 mGal in a standard deviation of 1.5 mGal.展开更多
The World Artificial Intelligence Conference 2025(WAIC 2025)and related exhibits and activities were convened in Shanghai on July 26-29.Taking“global solidarity in the AI era”as the theme,the conference built an int...The World Artificial Intelligence Conference 2025(WAIC 2025)and related exhibits and activities were convened in Shanghai on July 26-29.Taking“global solidarity in the AI era”as the theme,the conference built an international platform for cooperation and exchange,bringing China’s wisdom and Shanghai’s solutions to the world.During the conference,the International Forum on Standardization of Artificial Intelligence and the Emerging Markets and Developing Countries Forum on Bridging the AI Divide were held,gathering wisdom for AI to benefit humanity,and contributing to forming a global consensus.展开更多
Introduction The mission of the WHO International Clinical Trials Registry Platform is to ensure that a complete view of research is accessible to all those involved in health care decision making. This will improve r...Introduction The mission of the WHO International Clinical Trials Registry Platform is to ensure that a complete view of research is accessible to all those involved in health care decision making. This will improve research transparency and will ultimately strengthen the validity and value of the scientific evidence base. The registration of all interventional trials is a scientific, ethical and moral responsibility.展开更多
Objectives: Our aim was to clarify the study characteristics of countries that have registered clinical trials studies and to calculate the percentage of clinical trials that were registered in each country’s registr...Objectives: Our aim was to clarify the study characteristics of countries that have registered clinical trials studies and to calculate the percentage of clinical trials that were registered in each country’s registry, and try to find and evaluate the factors determining that percentage. Design and Methods: The present study is a cross-sectional study using data from clinical trials registered from January 1, 2011, to December 31, 2015. Only countries with more than 2000 registered trials were included for further study. Ten countries met that criterion: United States, Japan, Iran, Australia, New Zealand, China, India, Germany, United Kingdom, and Netherland. The percentage of clinical trials that were registered in each country’s registry was calculated, and the factors determining that percentage were sought and analyzed through an exploratory approach. Results: The chi-squared test of independence indicated that the rate of clinical trial registration significantly differed between countries. From the adjusted standardized residuals, the percentage of clinical trials that were registered in the country of origin was higher in the United States, India, Japan, and Australia/New Zealand than in the European Union and China. Conclusion: The United States requires that informed consent documents for clinical trials contain clinical trial registration numbers from ClinicalTrials.gov, which could be the reason for the extremely high percentage of registered clinical trials (94%). Since the European Union does not have this requirement, clinical trials conducted in the European Union do not have to be registered in the countries in which they are conducted.展开更多
At the beginning of the 1980s, China entered a new historical era of reform and opening up and socialist modernization drive. It became important and urgent for China to exchange and communicate with the international...At the beginning of the 1980s, China entered a new historical era of reform and opening up and socialist modernization drive. It became important and urgent for China to exchange and communicate with the international community. To meet the demand展开更多
Starting from 2008,the first combined exhibition "ITMA ASIA + CITME 2008" will be held at the Shanghai New International Expo Center in Shanghai,China,from 27 to 31 July 2008,which is scheduled to take place...Starting from 2008,the first combined exhibition "ITMA ASIA + CITME 2008" will be held at the Shanghai New International Expo Center in Shanghai,China,from 27 to 31 July 2008,which is scheduled to take place every two years,and featuring the unique strengths of the ITMA brand and the importance of Chinese textile machinery market.展开更多
The 16^th International Catalysis Congress (16th ICC) was successfully held in China in July 2016. This paper reviewed the development of catalytic science and technology of China from scratch to small then to large u...The 16^th International Catalysis Congress (16th ICC) was successfully held in China in July 2016. This paper reviewed the development of catalytic science and technology of China from scratch to small then to large under the efforts of several generations. In 1950s, catalysis discipline was first set up to train early catalytic professionals in Jilin University, Peking University and Xiamen University. Subsequently, a large research team was formed in colleges and universities, the Academy of Sciences, the Enterprise Research Institute to carry out a large number of catalytic researches. Along with the Chinese reform and opening-up, the spring of science came, and the state started to emphasize and strongly support scientific research. Chinese catalytic researchers began to enter the international catalytic academic exchange platform. Famous foreign scientists are invited to visit China and a large number of visiting scholars and foreign students have been sent to the United States, Europe and Japan, many of them have become well-known professors, and grown into catalytic academic elites. The first China-Japan-USA Symposium on Catalysis was held in Dalian in 1982, and it was expanded to become the Asian-Pacific Congress on Catalysis (APCAT), one of the three regional catalytic conferences in the world. After several generations of bidding for the organization of the International Catalytic Congress three times, China won the right to host the 16th ICC. It has effectively promoted the Chinese catalytic academic circles to the international academic ones and improved the influence of catalysis communities in China significantly. The great development in catalytic research and technology has condensed the efforts of several generations of catalysts. To make China a catalytically strong country, there is still a long way to go. We hope that the contemporary scientists can accomplish this historical task.展开更多
Objective:To analyze clinical trials of traditional medicine(including Chinese herbal medicine and nonpharmacological therapies)for the treatment of type 2 diabetes mellitus(T2DM)registered in the International Clinic...Objective:To analyze clinical trials of traditional medicine(including Chinese herbal medicine and nonpharmacological therapies)for the treatment of type 2 diabetes mellitus(T2DM)registered in the International Clinical Trials Registry Platform(ICTRP),and accordingly to explore their clinical trial registration characteristics,development trend and intervention status,in an attempt to provide references for future research design,diagnosis and management of traditional Chinese medicine therapy for T2DM.Methods:The clinical trials related to Chinese herbal medicine and nonpharmacological therapies for treating T2DM were retrieved on the ICTRP online from the time of database construction to August 13,2023,to analyze the time of registration,country and institution of the study,source of funding,type and design of the study,randomization and blinding methods,clinical staging,therapeutic measures,and main therapeutic effect indexes.Descriptive statistical analysis was performed using R4.3.0 and Excel software.Results:A total of 774 clinical trials for T2DM treatment were included,of which 127 were traditional herbal therapies and 647 were nonpharmacological therapies.The T2DM clinical trial registration institutions were distributed in 50 countries worldwide involving 15 clinical registration platforms,with the most registrations in Iran,China,and Australia,and the top 3 registration platforms were the Iranian Clinical Trial Registry,the Australian New Zealand Clinical Trials Registry,and the ICTRP.Universities(551,71.19%)were the main funding sources.Intervention studies(750,96.90%)were the primary study type,including randomized controlled trials(432,56.4%),and 225 studies mentioned the blinding method.A total of 530(68.48%)with a sample size≤100 were included.Study phases were predominantly phase 2 and phase 3(108,51.43%).The interventions of traditional medicine for T2DM were composed of Chinese herbal medicines(mainly ginseng and astragalus compound),nonpharmacological therapies(mainly exercise and diet therapies),and 2 or more comprehensive treatment regimes.According to the type of study design,the first 3 main therapeutic indexes were fasting blood glucose(286 times),glycated hemoglobin(282 times),and insulin resistance(120 times),and the top 3 secondary therapeutic indexes were body mass index(179 times),fasting blood glucose(175 times),and glycated hemoglobin(134 times).Conclusion:The study dissects the current status and trend of registration of clinical trials on traditional medicine for T2DM treatment.The number of trial registrations is on the rise year by year,and there are obvious geographical differences in the countries and platforms of registration.The trial design is mainly randomized controlled blind trials with a sample size of<100,and the main interventions are nonpharmacological therapies.Correct and standardized registration of clinical trials and timely reporting of study results are greatly important to facilitate the implementation of clinical trials,reduce publication bias,provide high-level diagnostic and therapeutic bases for clinical practice guidelines,and develop effective treatment strategies.This study is expected to help other scholars,health care professionals,patients,and the public to understand the latest research trends and hotspots in this field and provide certain references and inspirations for the future research design and clinical practice of traditional Chinese medicine in the treatment of T2DM.展开更多
Chinese Medical Journal Pulmonary and Critical Care Medicine is a peer-reviewed,open access journal which publishes high-quality clinical and basic research,review,and commentary articles on all aspects of respiratory...Chinese Medical Journal Pulmonary and Critical Care Medicine is a peer-reviewed,open access journal which publishes high-quality clinical and basic research,review,and commentary articles on all aspects of respiratory and critical care medicine.The journal provides an international platform for pulmonary physicians and researchers across the globe to present cutting-edge original research,insightful perspective and state-of-the-art reviews and to promote,share and discuss new advancements in all relevant areas.展开更多
基金Supported by the National Natural Science Foundation of China(Nos.42192535,41876136)the Guangdong Special Support Program(No.2019BT02H594)supported by the Key Special Projects of the Southern Marine Science and Engineering Guangdong Laboratory(Guangzhou)(for Introduced Talents Team)(Nos.GML2021GD0810,GML2019ZD0602)。
文摘To dampen periodic off-levelling motions within an inertial platform while undergoing horizontal accelerations of the same period and to achieve a levelling accuracy of a few tens of arcseconds with that system,an internally damped inertial platform for a marine scalar gravity system was the developed.Methods for attenuating horizontal acceleration and reducing off-levelling error by a satisfactory gyro-levelling loop,which are fundamental to the internally damped inertial platform,were designed and implemented.In addition,phase delays are introduced by the levelling loop.The resulting off-levelling gravity errors were analyzed and modeled.A series of tests on a motion simulator were performed in laboratory for a variety of simulated sea conditions.We found that the motion of the platform is a function of the amplitude and period of the simulated ship motions and ranges between 10 and 40 arcseconds.In addition,the phase lag between platform motion and ship motion is not constant but ranges 180°-270°,depending on the period and amplitude of the motion.Then,the platform,on which a gravimeter was mounted,was installed on the R/V Shiyan 2 to conduct a gravity survey in the South China Sea.Despite rough sea conditions,it was shown that in short periods of 2-30 s,the off-levelling angle was less than 30 arcseconds,and the phase lagged the horizontal acceleration by 230°-260°.From a repeated survey line and intersecting survey points,the estimated errors of gravity measurements were between 1.3 and 1.7 mGal.The marine measurements results were compared with those of satellite altimetry data and show a mean value of 0.5 mGal in a standard deviation of 1.5 mGal.
文摘The World Artificial Intelligence Conference 2025(WAIC 2025)and related exhibits and activities were convened in Shanghai on July 26-29.Taking“global solidarity in the AI era”as the theme,the conference built an international platform for cooperation and exchange,bringing China’s wisdom and Shanghai’s solutions to the world.During the conference,the International Forum on Standardization of Artificial Intelligence and the Emerging Markets and Developing Countries Forum on Bridging the AI Divide were held,gathering wisdom for AI to benefit humanity,and contributing to forming a global consensus.
文摘Introduction The mission of the WHO International Clinical Trials Registry Platform is to ensure that a complete view of research is accessible to all those involved in health care decision making. This will improve research transparency and will ultimately strengthen the validity and value of the scientific evidence base. The registration of all interventional trials is a scientific, ethical and moral responsibility.
文摘Objectives: Our aim was to clarify the study characteristics of countries that have registered clinical trials studies and to calculate the percentage of clinical trials that were registered in each country’s registry, and try to find and evaluate the factors determining that percentage. Design and Methods: The present study is a cross-sectional study using data from clinical trials registered from January 1, 2011, to December 31, 2015. Only countries with more than 2000 registered trials were included for further study. Ten countries met that criterion: United States, Japan, Iran, Australia, New Zealand, China, India, Germany, United Kingdom, and Netherland. The percentage of clinical trials that were registered in each country’s registry was calculated, and the factors determining that percentage were sought and analyzed through an exploratory approach. Results: The chi-squared test of independence indicated that the rate of clinical trial registration significantly differed between countries. From the adjusted standardized residuals, the percentage of clinical trials that were registered in the country of origin was higher in the United States, India, Japan, and Australia/New Zealand than in the European Union and China. Conclusion: The United States requires that informed consent documents for clinical trials contain clinical trial registration numbers from ClinicalTrials.gov, which could be the reason for the extremely high percentage of registered clinical trials (94%). Since the European Union does not have this requirement, clinical trials conducted in the European Union do not have to be registered in the countries in which they are conducted.
文摘At the beginning of the 1980s, China entered a new historical era of reform and opening up and socialist modernization drive. It became important and urgent for China to exchange and communicate with the international community. To meet the demand
文摘Starting from 2008,the first combined exhibition "ITMA ASIA + CITME 2008" will be held at the Shanghai New International Expo Center in Shanghai,China,from 27 to 31 July 2008,which is scheduled to take place every two years,and featuring the unique strengths of the ITMA brand and the importance of Chinese textile machinery market.
文摘The 16^th International Catalysis Congress (16th ICC) was successfully held in China in July 2016. This paper reviewed the development of catalytic science and technology of China from scratch to small then to large under the efforts of several generations. In 1950s, catalysis discipline was first set up to train early catalytic professionals in Jilin University, Peking University and Xiamen University. Subsequently, a large research team was formed in colleges and universities, the Academy of Sciences, the Enterprise Research Institute to carry out a large number of catalytic researches. Along with the Chinese reform and opening-up, the spring of science came, and the state started to emphasize and strongly support scientific research. Chinese catalytic researchers began to enter the international catalytic academic exchange platform. Famous foreign scientists are invited to visit China and a large number of visiting scholars and foreign students have been sent to the United States, Europe and Japan, many of them have become well-known professors, and grown into catalytic academic elites. The first China-Japan-USA Symposium on Catalysis was held in Dalian in 1982, and it was expanded to become the Asian-Pacific Congress on Catalysis (APCAT), one of the three regional catalytic conferences in the world. After several generations of bidding for the organization of the International Catalytic Congress three times, China won the right to host the 16th ICC. It has effectively promoted the Chinese catalytic academic circles to the international academic ones and improved the influence of catalysis communities in China significantly. The great development in catalytic research and technology has condensed the efforts of several generations of catalysts. To make China a catalytically strong country, there is still a long way to go. We hope that the contemporary scientists can accomplish this historical task.
基金This work was supported by China Academy of Chinese Medical Sciences Innovation Fund(CI2021A05501)TCM Clinical Basic Discipline Innovation Team Project of China Academy of Chinese Medical Sciences Innovation Fund(CI2021B003)Basic Research Funds for Free Exploration Project of Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences(Z0856,Z0863,Z0855).
文摘Objective:To analyze clinical trials of traditional medicine(including Chinese herbal medicine and nonpharmacological therapies)for the treatment of type 2 diabetes mellitus(T2DM)registered in the International Clinical Trials Registry Platform(ICTRP),and accordingly to explore their clinical trial registration characteristics,development trend and intervention status,in an attempt to provide references for future research design,diagnosis and management of traditional Chinese medicine therapy for T2DM.Methods:The clinical trials related to Chinese herbal medicine and nonpharmacological therapies for treating T2DM were retrieved on the ICTRP online from the time of database construction to August 13,2023,to analyze the time of registration,country and institution of the study,source of funding,type and design of the study,randomization and blinding methods,clinical staging,therapeutic measures,and main therapeutic effect indexes.Descriptive statistical analysis was performed using R4.3.0 and Excel software.Results:A total of 774 clinical trials for T2DM treatment were included,of which 127 were traditional herbal therapies and 647 were nonpharmacological therapies.The T2DM clinical trial registration institutions were distributed in 50 countries worldwide involving 15 clinical registration platforms,with the most registrations in Iran,China,and Australia,and the top 3 registration platforms were the Iranian Clinical Trial Registry,the Australian New Zealand Clinical Trials Registry,and the ICTRP.Universities(551,71.19%)were the main funding sources.Intervention studies(750,96.90%)were the primary study type,including randomized controlled trials(432,56.4%),and 225 studies mentioned the blinding method.A total of 530(68.48%)with a sample size≤100 were included.Study phases were predominantly phase 2 and phase 3(108,51.43%).The interventions of traditional medicine for T2DM were composed of Chinese herbal medicines(mainly ginseng and astragalus compound),nonpharmacological therapies(mainly exercise and diet therapies),and 2 or more comprehensive treatment regimes.According to the type of study design,the first 3 main therapeutic indexes were fasting blood glucose(286 times),glycated hemoglobin(282 times),and insulin resistance(120 times),and the top 3 secondary therapeutic indexes were body mass index(179 times),fasting blood glucose(175 times),and glycated hemoglobin(134 times).Conclusion:The study dissects the current status and trend of registration of clinical trials on traditional medicine for T2DM treatment.The number of trial registrations is on the rise year by year,and there are obvious geographical differences in the countries and platforms of registration.The trial design is mainly randomized controlled blind trials with a sample size of<100,and the main interventions are nonpharmacological therapies.Correct and standardized registration of clinical trials and timely reporting of study results are greatly important to facilitate the implementation of clinical trials,reduce publication bias,provide high-level diagnostic and therapeutic bases for clinical practice guidelines,and develop effective treatment strategies.This study is expected to help other scholars,health care professionals,patients,and the public to understand the latest research trends and hotspots in this field and provide certain references and inspirations for the future research design and clinical practice of traditional Chinese medicine in the treatment of T2DM.
文摘Chinese Medical Journal Pulmonary and Critical Care Medicine is a peer-reviewed,open access journal which publishes high-quality clinical and basic research,review,and commentary articles on all aspects of respiratory and critical care medicine.The journal provides an international platform for pulmonary physicians and researchers across the globe to present cutting-edge original research,insightful perspective and state-of-the-art reviews and to promote,share and discuss new advancements in all relevant areas.
